For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $41.2 in the prior trading day, Kymera Therapeutics Inc (NASDAQ: KYMR) closed at $40.69, down -1.24%. In other words, the price has decreased by -$1.24 from its previous closing price. On the day, 1.25 million shares were traded. KYMR stock price reached its highest trading level at $41.66 during the session, while it also had its lowest trading level at $39.84.
Ratios:
Our goal is to gain a better understanding of KYMR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.32 and its Current Ratio is at 8.32. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 30 ’25 when BVF PARTNERS L P/IL bought 317,167 shares for $44.00 per share. The transaction valued at 13,955,348 led to the insider holds 2,798,795 shares of the business.
BAKER BROS. ADVISORS LP bought 655,500 shares of KYMR for $28,842,000 on Jun 30 ’25. The Director now owns 6,117,295 shares after completing the transaction at $44.00 per share. On Jun 11 ’25, another insider, Ridloff Elena, who serves as the Director of the company, sold 4,500 shares for $50.00 each. As a result, the insider received 225,000 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 2909237248 and an Enterprise Value of 2329506304. For the stock, the TTM Price-to-Sale (P/S) ratio is 65.07 while its Price-to-Book (P/B) ratio in mrq is 2.96. Its current Enterprise Value per Revenue stands at 52.101 whereas that against EBITDA is -7.636.
Stock Price History:
The Beta on a monthly basis for KYMR is 2.18, which has changed by -0.1186918 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, KYMR has reached a high of $53.27, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is -6.82%, while the 200-Day Moving Average is calculated to be 5.41%.
Shares Statistics:
The stock has traded on average 857.47K shares per day over the past 3-months and 586180 shares per day over the last 10 days, according to various share statistics. A total of 70.56M shares are outstanding, with a floating share count of 58.87M. Insiders hold about 17.67% of the company’s shares, while institutions hold 94.97% stake in the company. Shares short for KYMR as of 1755216000 were 7611533 with a Short Ratio of 8.88, compared to 1752537600 on 7572642. Therefore, it implies a Short% of Shares Outstanding of 7611533 and a Short% of Float of 13.139999999999999.
Earnings Estimates
Current recommendations for the stock of the company come from 16.0 analysts. The consensus estimate for the next quarter is -$0.91, with high estimates of -$0.62 and low estimates of -$1.09.
Analysts are recommending an EPS of between -$2.48 and -$3.82 for the fiscal current year, implying an average EPS of -$3.39. EPS for the following year is -$4.01, with 16.0 analysts recommending between -$3.13 and -$5.16.
Revenue Estimates
18 analysts predict $19.65M in revenue for the current quarter. It ranges from a high estimate of $95M to a low estimate of $5M. As of the current estimate, Kymera Therapeutics Inc’s year-ago sales were $3.74MFor the next quarter, 18 analysts are estimating revenue of $17.52M. There is a high estimate of $39.3M for the next quarter, whereas the lowest estimate is $4.4M.
A total of 19 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $190M, while the lowest revenue estimate was $43.58M, resulting in an average revenue estimate of $82.09M. In the same quarter a year ago, actual revenue was $47.07M
